TY - JOUR
T1 - Factors predicting the therapeutic response to methotrexate in Japanese patients with rheumatoid arthritis
T2 - A hospital-based cohort study
AU - Hakamata, Jun
AU - Kaneko, Yuko
AU - Shimizu, Mikiko
AU - Yamaoka, Kunihiro
AU - Maruyama, Junya
AU - Takeuchi, Tsutomu
AU - Mochizuki, Mayumi
AU - Hashiguchi, Masayuki
N1 - Funding Information:
We are grateful to Ms. Harumi Kondo and research nurses of the Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, for helpful assistance in collecting patient information.
Publisher Copyright:
© 2018 The Pharmaceutical Society of Japan.
PY - 2018
Y1 - 2018
N2 - Methotrexate (MTX) is used widely as a first-line drug for the treatment of rheumatoid arthritis (RA) worldwide. There are large interindividual differences in the therapeutic response to MTX, but it is not known which factors influence them. We therefore investigated predictive factors associated with the therapeutic response to MTX in a hospital-based cohort study. Japanese adult RA outpatients prescribed MTX were enrolled and their characteristics were collected from the electronic medical records. The European League Against Rheumatism (EULAR) response criteria were used as the response to MTX therapy. The observation period was 1 year after beginning MTX administration. Sixteen types of single-nucleotide polymorphisms were investigated using the real-time PCR method. Associations between the MTX response and patient characteristics were evaluated using the multivariate logistic regression model. Among 70 Japanese adult RA outpatients, 52 were classified as MTX responders. In multivariate analysis, patients with the solute carrier family 19 member 1 (SLC19A1) 80G>A A/A genotype had a better response than those with the A/G or G/G genotype, and patients with the C allele of γ-glutamyl hydrolase (GGH) 16T>C had a better response than those with the T/T genotype.This study showed that the therapeutic response to MTX in Japanese RA patients was associated with the genetic polymorphisms of SLC19A1 80G>A and GGH 16T>C in actual clinical practice.
AB - Methotrexate (MTX) is used widely as a first-line drug for the treatment of rheumatoid arthritis (RA) worldwide. There are large interindividual differences in the therapeutic response to MTX, but it is not known which factors influence them. We therefore investigated predictive factors associated with the therapeutic response to MTX in a hospital-based cohort study. Japanese adult RA outpatients prescribed MTX were enrolled and their characteristics were collected from the electronic medical records. The European League Against Rheumatism (EULAR) response criteria were used as the response to MTX therapy. The observation period was 1 year after beginning MTX administration. Sixteen types of single-nucleotide polymorphisms were investigated using the real-time PCR method. Associations between the MTX response and patient characteristics were evaluated using the multivariate logistic regression model. Among 70 Japanese adult RA outpatients, 52 were classified as MTX responders. In multivariate analysis, patients with the solute carrier family 19 member 1 (SLC19A1) 80G>A A/A genotype had a better response than those with the A/G or G/G genotype, and patients with the C allele of γ-glutamyl hydrolase (GGH) 16T>C had a better response than those with the T/T genotype.This study showed that the therapeutic response to MTX in Japanese RA patients was associated with the genetic polymorphisms of SLC19A1 80G>A and GGH 16T>C in actual clinical practice.
KW - Effectiveness
KW - European League Against Rheumatism
KW - Japanese
KW - Methotrexate
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=85052717434&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052717434&partnerID=8YFLogxK
U2 - 10.1248/bpb.b18-00247
DO - 10.1248/bpb.b18-00247
M3 - Article
C2 - 30175777
AN - SCOPUS:85052717434
SN - 0918-6158
VL - 41
SP - 1414
EP - 1422
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
IS - 9
ER -